Clinical Trial

Yunu Extends Free Cancer Center Use of Platform for All Children’s Oncology Group Clinical TrialsYunu Extends Free Cancer Center Use of Platform for All Children’s Oncology Group Clinical Trials

Yunu Extends Free Cancer Center Use of Platform for All Children’s Oncology Group Clinical Trials

CARY, NC / ACCESSWIRE / September 12, 2024 / Yunu, a leading provider of clinical trial imaging workflow and data…

4 months ago
VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET InhibitorVYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

VYN202 was generally well tolerated with no drug-related adverse eventsPharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood Pharmacodynamic activity observed…

4 months ago
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-ZrMonopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr

Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr

WILMETTE, Ill., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing…

4 months ago
Sernova Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and FunctionSernova Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function

Sernova Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function

Abundant, richly vascularized and functioning islets observed throughout all chambers of Sernova’s Cell Pouch more than 5 years after islet…

4 months ago
Acasti to Present at the Life Sciences Investor ForumAcasti to Present at the Life Sciences Investor Forum

Acasti to Present at the Life Sciences Investor Forum

PRINCETON, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma…

4 months ago
Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgANVera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN

Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN

On track to announce topline results from ORIGIN 3 trial in Q2 2025Expect to present 96-week data from ORIGIN Phase…

4 months ago
Biogen Board Appoints Two New Independent DirectorsBiogen Board Appoints Two New Independent Directors

Biogen Board Appoints Two New Independent Directors

Dr. Lloyd Minor and Prof Sir Menelas Pangalos bring significant scientific expertise and considerable experience in medicine research and developmentCAMBRIDGE,…

4 months ago
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific MeetingIntellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting

Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting

First presentation of detailed Phase 2 results following previous positive topline announcement that study of NTLA-2002 met primary and all…

4 months ago